3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione Suppliers list
|
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Email: |
marketing@energy-chemical.com |
Products Intro: |
Product Name:Menaquinone 4-d7 2,3-Epoxide CAS:1233937-43-3 Purity:NULL Package:2.5mg Remarks:NULL
|
Company Name: |
CLEARSYNTH LABS LTD.
|
Tel: |
+91-22-45045900 |
Email: |
sales@clearsynth.com |
Products Intro: |
Product Name:"Menaquinone 4-d7 2,3-Epoxide" CAS:1233937-43-3
|
|
| 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione Basic information |
Product Name: | 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione | Synonyms: | 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione | CAS: | 1233937-43-3 | MF: | C31H40O3 | MW: | 460.66 | EINECS: | | Product Categories: | | Mol File: | 1233937-43-3.mol | |
| 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione Chemical Properties |
| 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione Usage And Synthesis |
Uses | Menaquinones are isoprenoid quinones of the naphthalene series and belongs to the K2 Vitamin homologs. Menaquinones were originally discovered as the anti-hemorrhagic factor and now encompasses a variety of physiological processes. Menaquinone 4-d7 2,3-Epoxide is the labelled analog of Menaquinone 4 2,3-Epoxide, the expoxide metabolite of Menaquinone 6 (M21895) in human plasma. Menaquinone 4 has four isoprene residue in its side chain and is also commonly refered to as menatetrenone. Menaquinone-4 is the most common type of vitamin K2 and is known as a hemostatic agent and is used as adjunctive therapy for the pain of osteoporosis. |
| 3,4,5,6-tetradeuterio-7a-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-1a-(trideuteriomethyl)naphtho[2,3-b]oxirene-2,7-dione Preparation Products And Raw materials |
Raw materials | 5,6,7,8-tetradeuterio-2-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-3-(trideuteriomethyl)naphthalene-1,4-dione |
|